- Home
- EQ vs CMBM Comparison
EQ vs CMBM Comparison
Compare EQ & CMBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- CMBM
- Stock Information
- Founded
- EQ 2017
- CMBM 2011
- Country
- EQ United States
- CMBM United States
- Employees
- EQ N/A
- CMBM N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- CMBM Radio And Television Broadcasting And Communications Equipment
- Sector
- EQ Health Care
- CMBM Technology
- Exchange
- EQ Nasdaq
- CMBM Nasdaq
- Market Cap
- EQ 24.8M
- CMBM 26.5M
- IPO Year
- EQ 2018
- CMBM 2019
- Fundamental
- Price
- EQ $0.59
- CMBM $0.75
- Analyst Decision
- EQ Buy
- CMBM Strong Buy
- Analyst Count
- EQ 2
- CMBM 3
- Target Price
- EQ $5.00
- CMBM $5.50
- AVG Volume (30 Days)
- EQ 117.7K
- CMBM 185.1K
- Earning Date
- EQ 11-13-2024
- CMBM 02-13-2025
- Dividend Yield
- EQ N/A
- CMBM N/A
- EPS Growth
- EQ N/A
- CMBM N/A
- EPS
- EQ N/A
- CMBM N/A
- Revenue
- EQ $45,914,000.00
- CMBM $172,215,000.00
- Revenue This Year
- EQ $4.76
- CMBM N/A
- Revenue Next Year
- EQ N/A
- CMBM $16.49
- P/E Ratio
- EQ N/A
- CMBM N/A
- Revenue Growth
- EQ 7.70
- CMBM N/A
- 52 Week Low
- EQ $0.56
- CMBM $0.66
- 52 Week High
- EQ $3.25
- CMBM $6.50
- Technical
- Relative Strength Index (RSI)
- EQ 33.48
- CMBM 29.36
- Support Level
- EQ $0.56
- CMBM $0.68
- Resistance Level
- EQ $0.67
- CMBM $0.81
- Average True Range (ATR)
- EQ 0.05
- CMBM 0.11
- MACD
- EQ -0.00
- CMBM -0.03
- Stochastic Oscillator
- EQ 15.79
- CMBM 10.79
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.